ESMO Full, Honorary and Emeritus members: we are now accepting nominations for the 2015 ESMO Awards
There are many good reasons to become an ESMO member. Find out why you should join Europe's leading medical oncology society
ESMO’s flagship scientific journal, Annals of Oncology, publishes editorials, reviews, original articles and letters related to oncology
OncologyPRO, a 360° research solution designed around YOU, is your single gateway to essential research & knowledge
Did you know that PD-1 was discovered in 1992? It is present in both, T- and B-cells and targeting the PD-1 pathways showed a clear evidence of clinical activity and a great promise in a vast range of cancer types, in particular the case of melanoma. J. Weber describes the promising future of this class of agents with many biomarkers available to test the clinical efficacy of PD-1 targeting antibodies.
27 Feb 2015
It is intended for the treatment of ALK-positive advanced NSCLC previously treated with crizotinib
25 Feb 2015
Intended for patients who have received at least two prior standard therapies, including bortezomib and an immunomodulatory agent
24 Feb 2015
The module by Massimo Broggini and Elisa Caiola is now available. View the presentation now and take the CME test!
23 Feb 2015
Bloom syndrome is an inherited disorder characterised by an increased risk of cancer and other health problems
20 Feb 2015
A 9-valent HPV vaccine tested in broad spectrum HPV vaccine study
19 Feb 2015
We have three open positions in the Communications Department at our head office in Lugano, Switzerland. Interested? You can find out more here...
06 Mar - 06 Mar 2015
13 Mar - 14 Mar 2015
27 Mar - 28 Mar 2015
15 Apr - 18 Apr 2015
07 May - 09 May 2015
01 Jul - 04 Jul 2015